Morgan Stanley Upgrades GlaxoSmithKline (GSK) to Equalweight
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $49.52 -0.96%
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley upgraded GlaxoSmithKline (NYSE: GSK) from Underweight to Equalweight.
For more ratings news on GlaxoSmithKline click here and for the rating history of GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $44.43 yesterday.
For more ratings news on GlaxoSmithKline click here and for the rating history of GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $44.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- Desjardins Upgrades PRO REIT (PRV-U:CN) to Buy
- CIBC Upgrades PRO REIT (PRV-U:CN) to Outperformer
Create E-mail Alert Related Categories
UpgradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
